Clinical trials: Liraglutide
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
This trial is conducted in the United States of America (USA). The aim of this trial is to determine the dose-response relationship for body weight and five escalating doses of NNC 90-1170 (liraglutide) in subjects with type 2…
- Trial name
- NCT01511198
- Testing
- liraglutide, metformin
- Where
- 39 sites in United States
- Volunteers
- 223 people
- Sponsor
- Novo Nordisk A/S
Obesity, Type 2 Diabetes
Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes
The aim of this study is to investigate if endogenous Glucagon Like Peptide -1 (GLP-1) has an effect on brain satiety and reward systems and if there are alterations in obese patients with type 2 diabetes (T2DM).
- Trial name
- LIBRA (NCT01363609)
- Testing
- Liraglutide treatment 12 weeks, insulin glargine treatment, GLP-1 receptor antagonist
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Type 2 Diabetes Patients, Overweight and Obesity
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin…
- Conditions
- Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)
- Trial name
- LiraGooD (NCT03087032)
- Testing
- Liraglutide, insulin glargine
- Where
- China
- Volunteers
- 164 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Diabetes, Diabetes Mellitus, Type 2
The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with…
- Trial name
- NCT01617434
- Testing
- liraglutide
- Where
- 86 sites in United States, Argentina and 7 more
- Volunteers
- 451 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes
The objective of this study is to investigate the effects of physical training in patients with type 2 diabetes during treatment with the GLP-1 receptor agonist liraglutide (Victoza®) in a 16-weeks double-blinded, randomized…
- Trial name
- NCT01455441
- Testing
- Training and liraglutide
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Tina Vilsboll
Diabetes, Diabetes Mellitus, Type 2
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.
- Trial name
- LEADER® (NCT01179048)
- Testing
- liraglutide
- Where
- 428 sites in United States, Australia and 31 more
- Volunteers
- 9,341 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus
Patients with diabetes are susceptible to dementia, but regular therapy fails to reduce the risk of dementia. In previous observational study, the investigators found that liraglutide can improve cognitive function in patients…
- Trial name
- NCT05360147
- Testing
- Liraglutide, Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Third Military Medical University
Endometrioid Endometrial Adenocarcinoma
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
This study will explore the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) used concurrently with levonorgestrel intrauterine device in patients with poor surgical candidacy for a hysterectomy or patients who are…
- Trial name
- NCT07107334
- Testing
- Glucagon-like peptide 1 receptor agonist
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Hypoglycemia, Obesity
Treatment of Hypoglycemia Following Gastric Bypass Surgery
Obesity is increasing worldwide and consequently the need for efficient treatment opportunities. Roux-en-Y gastric bypass (RYGB) is one of the most commonly performed bariatric procedures used in the treatment of severe obesity.
- Conditions
- Hypoglycemia, Obesity, Surgery
- Trial name
- NCT02527993
- Testing
- Glucobay (acarbose), Januvia (sitagliptin), Verapamil HEXAL (verapamil)
- Volunteers
- 11 people
- Sponsor
- Zealand University Hospital
Obesity, Adolescent
Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone
The aim of the study is to investigate the effects of preoperative Saxenda (liraglutide). There are two groups, one group receives Saxena in addition to dietary measures when first seeking the operation, one group only diet.
- Trial name
- NCT06865365
- Testing
- Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions, Dietologic measures and lifestyle optimization for weight loss
- Volunteers
- 72 people
- Sponsor
- Medical University of Vienna
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) and insulin degludec (IDeg) in subjects with…
- Trial name
- DUAL™ II (NCT01392573)
- Testing
- insulin degludec/liraglutide, insulin degludec
- Where
- 86 sites in United States, Bulgaria and 5 more
- Volunteers
- 413 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)
This trial is conducted in Asia. The aim of this trial is to evaluate safety and effectiveness of Victoza® in patients with type 2 diabetes mellitus (T2DM) in combination with antidiabetes agents other than sulfonylurea under…
- Trial name
- NCT02321878
- Testing
- liraglutide
- Where
- 5 sites in Japan
- Volunteers
- 1,092 people
- Sponsor
- Novo Nordisk A/S
Smoking Cessation, Weight, Body
Daily Liraglutide for Nicotine Dependence
This clinical research trial examines the effects of the GLP-1 receptor agonist liraglutide on smoking behavior, food intake, and weight gain.
- Trial name
- DAL (NCT03712098)
- Testing
- Liraglutide, Smoking Cessation Counseling
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Rebecca Ashare
Polycystic Ovary Syndrome, Obesity
Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity
Weight reduction is the most important treatment target when polycystic ovary syndrome (PCOS) is linked to obesity. Liraglutide (LIRA) in dose of 3 mg was recently approved as an anti-obesity drug.
- Trial name
- NCT02909933
- Testing
- liraglutide, metformin and liraglutide
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana
Osteoarthritis, Obesity
Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss
This is a substudy to a randomised trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864).
- Trial name
- IM-LOSEIT-I (NCT02928471)
- Testing
- Intensive dietary intervention
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Henrik Gudbergsen
Diabetes, Diabetes Mellitus, Type 2
Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate the safety profile of liraglutide under normal conditions of use.
- Trial name
- Lead-Ph (NCT01345734)
- Testing
- liraglutide
- Where
- Philippines
- Volunteers
- 1,056 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of the trial is to assess the incidence rate and type of SADRs (serious adverse drug reactions).
- Trial name
- NCT01403025
- Testing
- liraglutide
- Where
- Japan
- Volunteers
- 4,121 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Overweight
Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes
Obesity is one of the characteristics of type 2 diabetes mellitus. Most of the obese diabetes patients are combined with dyslipidemia or hypertension.
- Conditions
- Type 2 Diabetes, Overweight, Obesity, Masked Hypertension
- Trial name
- NCT02503943
- Testing
- "Liraglutide" and "Mitiglinide", "Metformin" and "Mitiglinide", "Mitiglinide"
- Volunteers
- 90 people
- Sponsor
- Third Affiliated Hospital of Third Military Medical University
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The purpose of the trial is to investigate the efficacy and safety of liraglutide in combination with insulin therapy compared to insulin alone in Japanese subjects with type 2 diabetes mellitus.
- Trial name
- NCT01572740
- Testing
- liraglutide, insulin
- Where
- 23 sites in Japan
- Volunteers
- 257 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Medically Reproducing Bariatric Surgery
Type 2 diabetes (DM2) is a chronic disease affecting 29 million Americans and a leading cause of blindness, kidney failure, and limb loss (Engelgau et al 2004).
- Trial name
- MRB (NCT03225209)
- Testing
- OPTIFAST
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Moahad S Dar